In June 2018, we established Ajinomoto Koji Bio Co., Inc. as a joint venture between Ajinomoto Co., Inc. and Koji Bio Co., Inc. We combined Ajinomoto Co., Inc.'s high-quality amino acids as the foundation for culture media raw materials and their formulation development technology with Koji Bio Co., Inc.'s advanced liquid culture media production technology to launch a contract manufacturing company for clinical culture media necessary for regenerative medicine. Currently, we are engaged in contract manufacturing of liquid media and buffers for customers in cell therapy and biopharmaceuticals, enhancing our significance in the industry.